Vivos Therapeutics reports Q3 revenue growth, regains Nasdaq compliance

Vivos Therapeutics (VVOS) reported Q3 2026 revenue of $6.4M, up 24% from Q2 2026. Operating loss improved 18% YoY to $3.9M. Nine-month revenue rose 23% to $16.7M. Gross margin was 52% in Q3. Net loss was $2.0M, improved from $5.4M in Q3 2025. Cash fell to $0.2M. Nasdaq compliance regained.

Original reporting
Published Nov 16, 2026, 11:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VVOS
Bullish
medium confidence
Mentioned
$VVOS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VVOSBullishMed
01

Why it matters

The quarter shows revenue growth and cost reductions, while Nasdaq compliance reduces a key technical overhang. However, liquidity is extremely tight and gross margin declined due to lower product revenue, which may drive skepticism about sustainability.

02

Market read

Traders may reprice VVOS on reduced listing-risk and improved operating trajectory, while monitoring cash runway and margin quality for follow-through.

03

What to watch

The $2.9M other income from Employee Retention Credit reversal can mask underlying operating momentum; investors may focus on recurring gross margin and cash burn rather than headline net loss improvement.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session positioning following the Q3 release and Nasdaq compliance update

Background

Vivos Therapeutics is a medical device company focused on sleep apnea treatment, with recent strategy described as shifting away from appliance sales to dentists.

Company-level read

Ticker impact

$VVOSBullishMedium confidence
Context

Vivos reported Q3 revenue of $6.4M (+24% QoQ), improved operating loss, and said Nasdaq compliance was regained via the equity requirement.

Expected impact

Likely modest upside bias as compliance risk fades, tempered by liquidity concerns and gross margin pressure.

Evidence & confidence

The article combines a fresh quarterly operating update with a specific Nasdaq compliance milestone, but also highlights cash at $0.2M and gross margin down vs prior year.

Market effects

Sleep-apnea medical device peers may see marginal sentiment lift for the category if Vivos’ cost actions and dentist-channel shift show traction.

Limited, company-specific impact likely confined to small-cap healthcare sentiment.

Low, no cross-border operational or regulatory linkage described.

Counterpoint

The Nasdaq compliance win may not offset balance-sheet fragility, since cash is only $0.2M and gross margin fell year over year.

Key entities

  • Vivos Therapeutics Inc.

    Reported Q3 revenue growth, improved operating loss, and regained Nasdaq minimum stockholders’ equity compliance.

  • Nasdaq

    Notified Vivos it regained compliance with the minimum stockholders’ equity requirement, subject to monitoring.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.